{"altmetric_id":23847607,"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["Biogen"],"first_seen_on":"2017-08-15T10:57:28+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1502721873,"links":["https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02410278?cond=dimethyl+fumarate+AND+montelukast&rank=1"],"nct_id":"NCT02410278","pubdate":"2015-04-02T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera (MITIGATE)","type":"clinical_trial_study_record"},"altmetric_score":{"score":7,"score_history":{"1y":7,"6m":7,"3m":7,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":7},"context_for_score":{"all":{"total_number_of_other_articles":8372629,"mean":7.0578283965246,"rank":1225262,"this_scored_higher_than_pct":84,"this_scored_higher_than":7071961,"rank_type":"exact","sample_size":8372629,"percentile":84},"similar_age_3m":{"total_number_of_other_articles":178256,"mean":12.357938144793,"rank":35241,"this_scored_higher_than_pct":79,"this_scored_higher_than":141883,"rank_type":"exact","sample_size":178256,"percentile":79},"this_journal":{"total_number_of_other_articles":24560,"mean":10.548248870068,"rank":4097,"this_scored_higher_than_pct":75,"this_scored_higher_than":18546,"rank_type":"exact","sample_size":24560,"percentile":75},"similar_age_this_journal_3m":{"total_number_of_other_articles":818,"mean":3.3097674418605,"rank":13,"this_scored_higher_than_pct":97,"this_scored_higher_than":799,"rank_type":"exact","sample_size":818,"percentile":97}}},"demographics":[],"counts":{"total":{"posts_count":1},"news":{"unique_users_count":1,"unique_users":["pharmacy_times"],"posts_count":1}},"posts":{"news":[{"title":"Montelukast to Manage Tecfidera GI Side Effects","url":"http:\/\/ct.moreover.com\/?a=31515667095&p=1pl&v=1&x=EA9kN9o4ejEwJiHvzpNtyQ","license":"public","citation_ids":[23847607],"posted_on":"2017-08-14T14:44:33+00:00","summary":"The immunomodulator dimethyl fumarate (Tecfidera, Biogen) has been available for the treatment of relapsing forms of multiple sclerosis since 2013.","author":{"name":"Pharmacy Times","url":"http:\/\/www.pharmacytimes.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/334\/normal\/Screen_Shot_2015-01-26_at_11.48.35.png?1422272928"}}]}}